In a secondary analysis of the CBTlate trial of 228 adults aged 60+ with late-life depression, those whose depression stayed high on CBT had higher baseline plasma NfL and lower CXCL5; adding CXCL5 improved prediction of the trajectory.
Secondary analysisn = 228
Martino-Adami et al. Exploring blood-based biomarkers in late-life depression: Correlates of psychotherapeutic treatment outcomes